SunTrust Robinson Reiterates a Buy Rating on Evolus Inc (EOLS)


In a report released yesterday, John Boris from SunTrust Robinson reiterated a Buy rating on Evolus Inc (NASDAQ: EOLS), with a price target of $27. The company’s shares closed yesterday at $20.28.

According to TipRanks.com, Boris is a 4-star analyst with an average return of 10.7% and a 67.9% success rate. Boris covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Revance Therapeutics, and Merck & Company.

Evolus Inc has an analyst consensus of Strong Buy, with a price target consensus of $29.67, implying a 46.3% upside from current levels. In a report issued on July 23, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $35 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $39.50 and a one-year low of $6.75. Currently, Evolus Inc has an average volume of 612.6K.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EOLS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts